Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Case ReportBrain

Abrupt Regression of a Meningioma after Discontinuation of Cyproterone Treatment

A.M.G. Gonçalves, P. Page, V. Domigo, J.-F. Méder and C. Oppenheim
American Journal of Neuroradiology September 2010, 31 (8) 1504-1505; DOI: https://doi.org/10.3174/ajnr.A1978
A.M.G. Gonçalves
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Page
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Domigo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.-F. Méder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Oppenheim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

SUMMARY: The multiplicity of meningiomas or abrupt lesion growth in patients treated with cyproterone acetate suggests that this progestative treatment may promote lesion growth. We report the rapid regression of an incidental meningioma after discontinuation of a 10-year cyproterone acetate treatment. This unique observation suggests that conservative management of meningiomas may be the best option among users of high doses of cyproterone acetate, given that spontaneous regression may occur after hormonal treatment discontinuation.

Abbreviations

FLAIR
fluid-attenuated inversion recovery

Cyproterone acetate is a synthetic progestin with a powerful antiandrogen property, which is indicated for the treatment of inoperable prostate carcinoma, the reduction of sexual drive in men, or severe signs of androgenization in women. It is occasionally prescribed in male-to-female transsexual patients. It is also found in smaller quantities in combined oral contraceptives and for treating seborrhea, acne, hirsutism, and moderate androgen-related alopecia. Recent observations of meningioma, often multiple, among users of high doses of cyproterone acetate have raised the suspicion that it may promote the rapid growth of pre-existing or new meningioma.1 Here, we report the rapid regression of a meningioma after discontinuation of a 10-year cyproterone acetate treatment. This unique observation strengthens the link between cyproterone acetate and intracranial meningioma.

Case Report

A 46-year-old woman was admitted to the stroke unit of our institution for sudden transient neurologic symptoms, including left upper limb paresthesia. Her medical history was unremarkable. During the previous 10 years, she had been taking oral cyproterone acetate (50 mg/day), which acts as a progesterone agonist, in combination with substitutive estradiol, for androgenetic alopecia. Brain MR imaging, performed on admission, showed 2 punctuate cortical acute ischemic strokes (not illustrated) in the right superficial middle cerebral artery territory, corroborating the acute neurologic presentation. A right frontal extracranial tumor was also found incidentally (Fig 1). The tumor presented as a dural-based mass with cortical buckling and a thin rim of trapped CSF. It appeared as an isointense mass on the T1-weighted sequence, slightly hyperintense on the FLAIR sequence, with homogeneous contrast enhancement on a postgadolinium 3D T1-weighted sequence, and surrounded by a rim of peritumoral vasogenic edema on the FLAIR sequence. These imaging characteristics strongly favored the diagnosis of a frontal meningioma. The etiologic vascular work-up was negative apart from a patent foramen ovale. Because of its inherent thromboembolic risk, the hormonal treatment was discontinued, and the patient was discharged from the hospital under low-dose antiplatelets. On a serial MR imaging follow-up, the frontal mass had unexpectedly shrunk (16 cm3 at admission, 3.1 cm3 at 3 months, and 1.9 cm3 [88% volume reduction] at 6 months) and the peritumoral edema had disappeared. The patient was free of symptoms.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Extra-axial lesion of the olfactory groove, homogeneously enhanced on axial and T1-weighted sequences after administration of gadolinium and reformatted in the axial (A and B) and sagittal (C and D) planes. The lesion volume decreased rapidly from 16 cm3 (A and C) on admission to 3 cm3 (81% reduction in volume) at 3 months (not shown) and to 1.9 cm3 (88% reduction in volume) (B and D) at 6 months after hormonal treatment withdrawal.

Discussion

A meningioma is a benign tumor usually arising from the arachnoid cap cells or meningothelial cells. The relationship between meningioma and sex hormones is well known, with a higher female-to-male ratio, especially during the female reproductive years. Meningiomas may enlarge during hormonal influx, particularly during pregnancy and in the luteal phase of the menstrual cycle.2 In line with this, spontaneous regression of meningiomas has been reported after pregnancy.3 Because meningiomas often express progesterone receptors and, albeit to a lesser extent, estrogen receptors,4,5 it has been postulated that these hormones may influence the increase in tumor size by increasing blood volume and extracellular and intracellular fluid as well as by increasing proliferation of the tumor tissue.

As with breast cancer, exogenous female steroid hormones, especially progestogens, may play a role in the occurrence of meningioma.6,7 The risk of meningioma is increased among postmenopausal women who have used hormonal treatment replacement therapy and among women who have used long-acting contraceptives.7 The suspicion that high daily doses of cyproterone acetate for long periods could be responsible for the development of meningiomas, and especially multiple meningiomas, was reported in 2008.1 Froelich et al1 reported multiple meningiomas in 9 female patients treated with cyproterone acetate. Before treatment withdrawal, an increase in tumor size and/or the development of new meningiomas was observed in all 6 patients with available imaging follow-up. Treatment withdrawal was associated with lesion size/number stabilization. In 2007, the abrupt growth of a meningioma was reported in a male-to-female transsexual patient who had been taking high doses (100 mg) of cyproterone acetate.8 Despite evidence that antiprogesterone treatment reduces the size of meningioma, both in vitro and in vivo, such hormonotherapy is not part of the conservative management of meningioma.9

Reports of spontaneous regression of meningiomas in the literature are rare. Apart from spontaneous resolution after intratumoral hemorrhage,10 only 2 cases of regression have been reported in association with progestative hormonal treatment withdrawal. In a female case of lymphangioleiomyomatosis, the growth of multiple meningiomas was observed during a 4-year period after administration of medroxyprogesterone acetate, followed by a spontaneous regression after hormonal withdrawal.11 Shimizu et al12 reported a similar regression of meningioma during a 2-year period in an 80-year-old man after suspension of progesterone agonist therapy, administered for benign prostatic hyperplasia.12 No previous cases of meningioma regression have been observed after discontinuation of treatment with cyproterone acetate.

Our observation of rapid meningioma regression after hormonal treatment discontinuation reinforces the link between meningioma and cyproterone acetate. Lesion-volume regression might be due to a rapid decrease of tumor growth induced by steroid receptors.13 We cannot formally exclude the possibility that estradiol discontinuation may have played a role in the lesion regression. Any such role is likely to have been minor, given that the patient was taking a low dose of substitutive estrogen therapy to counterbalance the antiestrogenic effect of cyproterone. Furthermore, estrogen receptors are often minimally present or absent in meningioma.

Taken together, the multiplicity of meningiomas and rapid lesion growth in patients treated with cyproterone acetate and, as shown here, the rapid lesion regression following treatment withdrawal suggest that this treatment may actively stimulate, and its withdrawal inhibit, the meningioma cell cycle. The link between meningioma and cyproterone acetate may be stronger than that with other progestative therapies. If confirmed, this may have several practical implications: 1) Systematic screening for meningiomas may be useful before cyproterone therapy is considered. 2) The hormonal history should be analyzed in all patients with meningioma. 3) If a meningioma is found with the patient under cyproterone acetate medication, conservative tumor management with serial MR imaging follow-up could be an option, given that regression may occur after treatment discontinuation.

References

  1. 1.↵
    1. Froelich S,
    2. Dali-Youcef N,
    3. Boyer P,
    4. et al
    . Does cyproterone acetate promote multiple meningiomas? In: Proceedings of the 10th European Congress of Endocrinology, Berlin, Germany. May 3–7, 2008
  2. 2.↵
    1. Wigertz A,
    2. Lonn S,
    3. Hall P,
    4. et al
    . Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 2008;17:2663–70
    Abstract/FREE Full Text
  3. 3.↵
    1. Smith JS,
    2. Quinones-Hinojosa A,
    3. Harmon-Smith M,
    4. et al
    . Sex steroid and growth factor profile of a meningioma associated with pregnancy. Can J Neurol Sci 2005;32:122–27
    PubMed
  4. 4.↵
    1. Blankenstein MA,
    2. Verheijen FM,
    3. Jacobs JM,
    4. et al
    . Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000;65:795–800
  5. 5.↵
    1. Hatiboglu MA,
    2. Cosar M,
    3. Iplikcioglu AC,
    4. et al
    . Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. Surg Neurol 2008;69:356–62
    CrossRefPubMed
  6. 6.↵
    1. Moss J,
    2. DeCastro R,
    3. Patronas NJ,
    4. et al
    . Meningiomas in lymphangioleiomyomatosis. JAMA 2001;286:1879–81
    CrossRefPubMed
  7. 7.↵
    1. Wigertz A,
    2. Lonn S,
    3. Mathiesen T,
    4. et al
    . Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006;164:629–36
    Abstract/FREE Full Text
  8. 8.↵
    1. Gazzeri R,
    2. Galarza M,
    3. Gazzeri G
    . Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 2007;357:2411–12
    CrossRefPubMed
  9. 9.↵
    1. Matsuda Y,
    2. Kawamoto K,
    3. Kiya K,
    4. et al
    . Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994;80:527–34
    PubMed
  10. 10.↵
    1. de Almeida JP,
    2. Petteys RJ,
    3. Sciubba DM,
    4. et al
    . Regression of intracranial meningioma following intratumoral hemorrhage. J Clin Neurosci 2009;16:1246–49
    CrossRefPubMed
  11. 11.↵
    1. Pozzati E,
    2. Zucchelli M,
    3. Schiavina M,
    4. et al
    . Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report. Surg Neurol 2007;68:671–74
    CrossRefPubMed
  12. 12.↵
    1. Shimizu J,
    2. Matsumoto M,
    3. Yamazaki E,
    4. et al
    . Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 2008;48:227–30
    CrossRefPubMed
  13. 13.↵
    1. Jay JR,
    2. MacLaughlin DT,
    3. Riley KR,
    4. et al
    . Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 1985;62:757–62
    PubMed
  • Received August 13, 2009.
  • Accepted after revision August 17, 2009.
  • Copyright © American Society of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 31 (8)
American Journal of Neuroradiology
Vol. 31, Issue 8
1 Sep 2010
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Abrupt Regression of a Meningioma after Discontinuation of Cyproterone Treatment
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
A.M.G. Gonçalves, P. Page, V. Domigo, J.-F. Méder, C. Oppenheim
Abrupt Regression of a Meningioma after Discontinuation of Cyproterone Treatment
American Journal of Neuroradiology Sep 2010, 31 (8) 1504-1505; DOI: 10.3174/ajnr.A1978

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Abrupt Regression of a Meningioma after Discontinuation of Cyproterone Treatment
A.M.G. Gonçalves, P. Page, V. Domigo, J.-F. Méder, C. Oppenheim
American Journal of Neuroradiology Sep 2010, 31 (8) 1504-1505; DOI: 10.3174/ajnr.A1978
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • Abbreviations
    • Case Report
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Petroclival meningioma regression after combined oestrogen and nomegestrol acetate interruption
  • Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study
  • Crossref (37)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Endocrinology of Transgender Medicine
    Guy T’Sjoen, Jon Arcelus, Louis Gooren, Daniel T Klink, Vin Tangpricha
    Endocrine Reviews 2019 40 1
  • Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study
    Alain Weill, Pierre Nguyen, Moujahed Labidi, Benjamin Cadier, Thibault Passeri, Lise Duranteau, Anne-Laure Bernat, Isabelle Yoldjian, Sylvie Fontanel, Sébastien Froelich, Joël Coste
    BMJ 2021
  • Hormonal therapies and meningioma: Is there a link?
    Lucía Cea-Soriano, Tilo Blenk, Mari-Ann Wallander, Luis A. García Rodríguez
    Cancer Epidemiology 2012 36 2
  • Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients
    Anne Laure Bernat, Kenichi Oyama, Selma Hamdi, Emmanuel Mandonnet, Dominique Vexiau, Marc Pocard, Bernard George, Sebastien Froelich
    Acta Neurochirurgica 2015 157 10
  • Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature
    P. V. ter Wengel, E. Martin, L. Gooren, M. Den Heijer, S. M. Peerdeman
    Andrologia 2016 48 10
  • Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
    Gloria Aranda, Irene Halperin, Esther Gomez-Gil, Felicia A. Hanzu, Núria Seguí, Antonio Guillamon, Mireia Mora
    Frontiers in Endocrinology 2021 12
  • Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents
    Lloyd J.W. Tack, Robin Heyse, Margarita Craen, Karlien Dhondt, Heidi Vanden Bossche, Jolien Laridaen, Martine Cools
    The Journal of Sexual Medicine 2017 14 5
  • Estrogen and Progesterone Therapy and Meningiomas
    Mirella Hage, Oana Plesa, Isabelle Lemaire, Marie Laure Raffin Sanson
    Endocrinology 2022 163 2
  • Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review
    Ilaria Mancini, Antonino Rotilio, Irene Coati, Renato Seracchioli, Valentina Martelli, Maria Cristina Meriggiola
    Gynecological Endocrinology 2018 34 6
  • Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients
    Thibault Passeri, Pierre-Olivier Champagne, Anne-Laure Bernat, Shunya Hanakita, Henri Salle, Emmanuel Mandonnet, Sébastien Froelich
    Acta Neurochirurgica 2019 161 4

More in this TOC Section

  • Statin Therapy Does Not Affect the Radiographic and Clinical Profile of Patients with TIA and Minor Stroke
  • Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease
  • White Matter Alterations in the Brains of Patients with Active, Remitted, and Cured Cushing Syndrome: A DTI Study
Show more BRAIN

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner
  • Book Reviews

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire